Loading
GB
Giant Biogene Holding Co., Ltd Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by YAN JIANYA, was filed 28 Oct 2025.
Giant Biogene Holding Co., Ltd: what insiders have been doing
Giant Biogene Holding Co., Ltd is a Food & Beverage company. Its directors and officers file their transactions with HKEX. In the past year (21 October 2025 to 21 October 2026), 2 filings came from 1 insider.
Only purchases show up on the open market, 2 purchases in all worth €4.5M, filed by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 senior executive. The largest single trade was a purchase of €2.4M by YAN Jianya, published on 28 October 2025.
The latest purchase dates back some time: it was published 358 days ago, on 28 October 2025.
Across the 1,315 companies tracked on its exchange, the median is 4 filings; at 2 filings, this issuer sits below that mark. Since 2022, the database holds 13 purchases and 7 sales by insiders of the company.
For comparison within the same sector, see the insider buying recorded at Village Farms International, Inc. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Insider Decl.
29
Thresholds
n/a
Buy Volume
€480M
13 ops. · all time
Sell Volume
€475M
7 ops. · all time
Who traded when
BuySaleYan Jianya9 buys1 sale
Since the insiders bought
- -40.5%Entry HK$37.54 · Close 21 Oct 2026 HK$22.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Giant Biogene Holding Co., Ltd Buy (bullish), based on 13 analysts. Average price target: HK$36.82.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,083 of 26,283 companies
80.2
score / 100
Value68
Quality92
FCF yld5.6%
Earn yld8.0%
EV/EBITDA9.9x
ROE18%
Gross mgn80%
Net mgn35%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$22.60
Analyst consensus
13 analystsBuy
HK$25.00Target HK$36.82(+63%)HK$46.00
Income statement
RevenueHK$5.5B
Gross profitHK$4.4B80% margin
EBITDAHK$2.4B44% margin
Net incomeHK$1.9B31.4% margin
Valuation
PER (trailing)12.9x
PER (forward)10.0x
P/Book2.2x
Beta0.75
Balance sheet & cash
Market capHK$24B
Total debtHK$9.7M
Free Cash FlowHK$1.4B
Debt / Equity0%
Profitability & ownership
ROE18.0%
ROA9.8%
% insiders56.0%
% institutions10.0%
Last declaration on 28 October 2025
Declarations29 total
560,000 shares@ HK$38.9990.3% of flowShareXHKGHKEX:DA20251028E00055
Canonical exit: 25 Jan 2026 (T+90)
500,000 shares@ HK$38.500.2% of flowShareXHKGHKEX:DA20251022E00579
Canonical exit: 20 Jan 2026 (T+90)
760,000 shares@ HK$41.97950.4% of flowShareXHKGHKEX:DA20251017E00446
Canonical exit: 14 Jan 2026 (T+90)
200,000 shares@ HK$54.000.1% of flowShareXHKGHKEX:DA20250928E00029
Canonical exit: 25 Dec 2025 (T+90)
200,000 shares@ HK$54.000.1% of flowShareXHKGHKEX:DA20250926E00121
Canonical exit: 24 Dec 2025 (T+90)
950,000 shares@ HK$54.85290.6% of flowShareXHKGHKEX:DA20250925E00151
Canonical exit: 23 Dec 2025 (T+90)
134,000 shares@ HK$50.890.1% of flowShareXHKGHKEX:DA20250626E00315
Canonical exit: 24 Sept 2025 (T+90)
922,600 shares@ HK$50.620.5% of flowShareXHKGHKEX:DA20250625E00402
Canonical exit: 23 Sept 2025 (T+90)
35,000,000 shares@ HK$66.6528.1% of flowShareXHKGHKEX:DA20250502E00322
Canonical exit: 27 Jul 2025 (T+90)
35,000,000 shares@ HK$66.6528.3% of flowShareXHKGHKEX:DA20250425E00269
240,000 shares@ HK$35.0560.7% of flowShareXHKGHKEX:DA20250124E00230
33,220,000 shares@ HK$49.4020.7% of flowShareXHKGHKEX:DA20240529E00113
Canonical exit: 22 Aug 2024 (T+90)
33,220,000 shares@ HK$49.4020.6% of flowShareXHKGHKEX:DA20240523E00444
600,000 sharesShareXHKGHKEX:DA20240103E00184
Canonical exit: 27 Mar 2024 (T+90)
3,113,465 shares@ HK$35.15100.0% of flowShareXHKGHKEX:DA20231114E00205
160,000 shares@ HK$35.1539.3% of flowShareXHKGHKEX:DA20231114E00196
8,540,498 sharesShareXHKGHKEX:DA20231006E00453
800,000 sharesShareXHKGHKEX:DA20231006E00455
25 of 29 declarations
About Giant Biogene Holding Co., Ltd
Giant Biogene Holding Co., Ltd is a company listed on the Hong Kong Stock Exchange, specializing in the biotechnology sector. It focuses on developing innovative solutions for health and agriculture.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
